- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Business Development Office
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel mucolytics for the treatment of respiratory diseases
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Partnerships and collaborations
- Royalties distribution
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Melanoma

Melanoma is an aggressive form of skin cancer. The disease can be effectively treated if detected early but is dangerous once it spreads throughout the body. Australia has one of the highest incidence rates of melanoma in the world, and more than 1400 Australians die from the disease each year. Our research aims to develop new strategies for treating advanced cases of melanoma.
Melanoma research at WEHI
Our researchers are:
- Investigating how specialised immune cells called natural killer cells prevent melanoma from spreading.
- Exploring whether natural killer cells could be harnessed to fight melanoma.
- Developing treatments that target the proteins keeping melanoma cells alive.
- Studying how melanomas evolve and develop resistance to therapies.
What is melanoma?
Melanoma is a type of skin cancer that arises in skin cells called melanocytes.
Melanocytes sit in the top layer of skin, called the epidermis. They produce a pigment which gives skin its colour and helps protect against ultraviolet (UV) damage. When melanocytes group together in clusters, they form a non-cancerous mole.
Occasionally melanocytes begin to grow abnormally and form a melanoma. Melanoma usually occurs on parts of the body that are exposed to the sun, but rare cases occur in body parts that receive less sun exposure, such as the inside of the mouth.
Melanoma is a rare type of skin cancer, but it is the most deadly. Melanoma is particularly dangerous because it can invade deeper layers of skin and spread to other parts of the body like the lung, liver and brain.
Excluding less deadly types of skin cancer, melanoma is the third most common cancer diagnosed in Australian men and women.
Symptoms of melanoma
The first sign of melanoma is usually a change in an existing mole, or the appearance of a new mole. Melanomas vary greatly in how they look, but many show features such as:
- Asymmetry
- Irregular shape or border
- Uneven colour
- Increased size
- Itching or bleeding
- Raised surface
As not all melanomas show these classic features, it is important that a doctor checks any moles that change in shape or grow over a period of more than one month. Suspicious moles should be removed and examined by a pathologist to look for signs of melanoma.
Risk factors for developing melanoma
Melanoma is caused by genetic changes in melanocytes. These genetic changes are caused by UV radiation from the sun or from other sources such as solariums.
Factors that increase the risk of developing melanoma include:
- Prolonged sun exposure, particularly during childhood.
- Having a large number of moles, especially those with irregular shape.
- Having fair or freckled skin, blue or green eyes and fair or red hair.
- Having a previous case of melanoma.
- Having a family history of skin cancer, especially melanoma.
How is melanoma treated?
If melanoma is detected early, it can usually be successfully removed by surgery. For this reason, survival from melanoma is relatively high, with 90 per cent of people alive five years after diagnosis.
Once melanoma has spread, however, the disease can be life-threatening.
Traditional chemotherapy drugs are generally not effective in treating melanoma, and until recently, there were few treatment options for advanced disease.
Several promising treatments have recently been developed for melanoma, including:
- Targeted therapies that block specific proteins that drive melanoma growth.
- Immunotherapies that activate the body’s own immune system to fight melanoma.
These new therapies have improved survival and reduced symptoms for many people diagnosed with advanced melanoma, however there are still many challenges.
Working towards improved outcomes
Drug resistance is a major problem for targeted therapies, with many people having a favourable initial response but then relapsing with resistant disease. Our researchers are using cutting-edge genome technology to investigate how melanomas evolve to become drug resistant. We are also developing new drugs targeting the pro-survival proteins that are often highly expressed in drug-resistant melanomas.
Our researchers are also exploring new forms of immunotherapy based on specialised immune cells called natural killer (NK) cells. NK cells patrol the body and kill damaged cells, including cancer cells and cells infected with viruses. Our researchers discovered that NK cells are essential to eliminate melanoma cells that have spread to the lungs. They are now investigating new treatments for melanoma that harness NK cells.
Support for people with melanoma
WEHI researchers are not able to provide specific medical advice to individuals. If you have melanoma or are supporting somebody with this disease, please contact the Cancer Council or consult your medical specialist.
Researchers:
Super Content:
Our bodies are constantly fighting off the development of cells that lead to tumours. Researchers have now discovered a protein ‘brake’ within Natural Killer cells that controls their ability to destroy their target tumour cells.
A new compound has been shown to block a protein essential for the growth of many cancers, including melanoma, blood, breast and lung cancers.
Researchers have discovered the mechanism that drives specialised immune cells that detect and kill cancer cells in the body, offering scientists a new way to develop potential drug targets and cancer treatments.
Computational biology has enabled our researchers to develop a new method to identify melanoma patients with improved rates of survival.